Abstract Doxazosin and related, quinazoline-based α 1
α 1 -Adrenoceptor antagonists have originally been used for the treatment of arterial hypertension. However, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) demonstrated that the α 1 -antagonist doxazosin provided less protection from cardiovascular events than the diuretic chlorthalidone (ALLHAT Research Group 2000) . Additionally, in the Vasodilator Heart Failure Trial 1, prazosin was shown to be associated with greater mortality among heart failure patients vs those treated with other vasodilators (Cohn et al. 1986 ). Therefore, α 1 -antagonists are no longer considered to be a firstline treatment in cardiovascular medicine. On the other hand, this class of drugs has later been introduced to treat voiding symptoms attributed to benign prostatic hyperplasia (BPH) where they have become the most widely used option of medical therapy. Initially, the therapeutic success of this drug class was assumed only to be a direct result of α 1 -adrenoceptor blockade resulting in smooth muscle relaxation within the prostate. In this model, smooth muscle relaxation, in turn, provides relief from obstructive lower urinary tract symptoms caused by the enlarged prostate (Kirby 1995) . Since the late 1990s, rapidly growing evidence has mounted to support the paradigm shift concept that certain α 1 -antagonists not only have action on smooth muscle but also have α 1 -adrenoceptor-independent effects including apoptosis induction and suppression of tissue vascularity.
Early studies in mice showed that doxazosin, an α 1 -adrenoceptor antagonist with a quinazoline-based structure, induced apoptosis in murine prostatic stromal and epithelial cells (Yang et al. 1997) . Small retrospective cohort studies in humans provided the initial evidence that the therapeutic benefit of doxazosin in BPH patients may involve an apoptotic action against both prostate stromal and epithelial cells (Kyprianou et al. 1998) . A series of subsequent studies have confirmed the proapoptotic activity of quinazoline α 1 -antagonists including doxazosin, terazosin (Chon et al. 1999) , and more recently, prazosin (Lin et al. 2007 ) in normal and malignant prostate cells. While the induction of apoptosis by doxazosin and chemically related compounds was initially shown in prostate cells and most of the subsequent work has also been conducted in such cells, later studies demonstrated doxazosin-induced apoptosis to also occur in a range of other normal and tumor cells, indicating that this may be a global effect that is not cell type-dependent. Such other cell types include cardiac myocytes (Rodriguez-Feo et al. 2000; Eiras et al. 2006 ) and the H9C2 cell line derived thereof (Yang et al. 2009 ), vascular endothelial cells (Keledjian et al. 2005) , bladder smooth muscle cells (Austin et al. 2004) , urothelial cancer cells (Siddiqui et al. 2005) , pituitary adenoma cells (Fernando and Heaney 2005) , breast cancer cells (Hui et al. 2008) , colon cancer cells, and HeLa cells (Gan et al. 2008) .
One of the most interesting aspects of this effect is the fact that apoptosis induction occurs independently of the α 1 -antagonistic properties of these drugs (Kyprianou and Benning 2000; Anglin et al. 2002) . Support for this concept emerges from evidence suggesting a significantly increased apoptotic index in prostatic cells exposed to doxazosin and terazosin (quinazoline-based α 1 -antagonists) but not following tamsulosin treatment (a sulfonamide-based α 1 -antagonist). Furthermore, the irreversible α 1 -antagonist phenoxybenzamine had no effect on the antigrowth action of doxazosin or terazosin (Kyprianou and Benning 2000) . Finally, it should be noted that doxazosin and related quinazoline α 1 -adrenoceptor antagonists block all subtypes of those receptors in the nanomolar range (Michel et al. 1995) whereas micromolar concentrations of these drugs are required to induced apoptosis in vitro (Kyprianou and Benning 2000; Benning and Kyprianou 2002) . In some animal studies, the induction of apoptosis in response to doxazosin treatment in vivo was achieved at relatively high concentrations and supratherapeutic doses (Yang et al. 1997; Benning and Kyprianou 2002) . Despite the initial reservations regarding this issue, one must recognize that the retrospective human studies have reported quinazolineinduced apoptosis in the prostate upon exposure to therapeutically relevant doses (Kyprianou et al. 1998; Chon et al. 1999) . While the reason for this discrepancy is not fully clear, it should be noted that many of those human in vivo studies have largely relied on the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) technique as an apoptosis marker, which may yield false-positive results in some cases (see below). Moreover, multiple large placebo-controlled studies have failed to detect reduction of prostate size upon long-term treatment with, e.g., doxazosin (McConnell et al. 2003) or alfuzosin (Roehrborn 2006) , which would argue against a clinically relevant degree of apoptosis induction upon standard therapeutic doses of these drugs.
Several studies have attempted to elucidate the cellular and molecular mechanisms underlying the apoptosis-inducing effects of doxazosin and related quinazolines. While in vitro approaches with cultured cell lines initially demonstrated that at least part of these effects occur directly by an interaction of the quinazolines with their target cells (Anglin et al. 2002; Partin et al. 2003) , subsequent studies in more complex models indicate additional indirect effects. For example, some experimental studies have identified anoikis (programmed cell death initiated by loss of cell-cell or cell-matrix adhesion; Frisch and Screaton 2001; Rennebeck et al. 2005) as one of the apoptotic mechanisms responsible for the suppression of prostate tumor growth and vascularity by the quinazoline α 1 -adrenoceptor antagonists, doxazosin and terazosin, independent of effects on cell proliferation (Tahmatzopoulos et al. , 2005 . Human bladder tumors exposed to terazosin also had a significant increase in apoptosis and decrease in tissue vascularity (Tahmatzopoulos et al. 2005) . Apoptosis induction in many tumor cell types along with the combination of direct and indirect (anoikis, reduced vascularity) cell death-promoting effects raises the possibility that quinazolines may be a drug class with clinically useful anticancer effects.
In this issue of the journal, Yang et al. (2009) have explored potential mechanisms of quinazoline-induced apoptosis. They report on a functional contribution of transforming growth factor-β (TGF-β) type I receptor/ ALK5-p38 MAPK phosphorylation signaling cascade in doxazosin-induced apoptosis in rat embryonic ventricular myoblasts. This represents a new signaling pathway for the "cell-killing action" of doxazosin and its quinazoline-based derivatives. However, this is not the first indication of the involvement of this multifunctional growth factor, TGF-β, in doxazosin's apoptotic effects. Indeed, the ligand itself, TGF-β, has been previously implicated in doxazosininduced apoptosis in prostate tumor epithelial cells and smooth muscle fibroblasts (Yang et al. 1997; Anglin et al. 2002; Partin et al. 2003) . The dissection of the type I TGF-β receptor as the primary upstream "executioner" in the apoptotic cascade triggered by doxazosin carries much promise and initiates momentum for the identification of the downstream effectors. The characterization of the signaling network operated by TGF-β via Smaddependent and Smad-independent mechanisms in conjunction with branches of MAP kinase pathways enables the therapeutic exploitation of this multifaceted growth factor during cancer progression. The challenge remains to identify effective therapeutic modalities that do not interfere with the positive effects of TGF-β as a tumor suppressor at the onset of tumorigenic growth while inhibiting the dysfunctional TGF-β in advanced cancer. Considering this ill-fated alliance between TGF-β and tumors, the temporal targeting of the TGF-β pathway should be implemented during the transition from tumor suppressor to tumor promoter and prior to its involvement in the metastatic process in the context of the tumor microenvironment. The biological repertoire of epithelial, stromal fibroblasts and endothelial cells linked to anoikis provides attractive targets for doxazosin's action during prostate tumor metastasis via the ability of the drug to engage TGF-β signaling.
While recognizing that the proapoptotic properties of α 1 -antagonists are exciting in the context of identification of novel cancer molecular therapeutics, one must also consider the negative effects that may result if these properties extend to other cell types. In vitro evidence indicated that doxazosin induced apoptosis in a time-dependent and dosedependent (1-40 µM) manner in HL-1 cells (continuously dividing, spontaneously contracting mouse cardiomyocytes). Other quinazoline α 1 -antagonists, terazosin and prazosin, in addition to doxazosin, were also linked to in vitro K + channel blockage in a 2004 study. In this study, all three quinazoline α 1 -antagonists blocked human ether-ago-go-related gene (HERG) K + channels, which are located in human cardiomyocytes and some adenocarcinomas. Blockage of current in HERG channels was demonstrated in both human embryonic kidney (HEK) cells and Xenopus oocytes in a concentration-dependent manner (Thomas et al. 2004) . HERG channel-blocking agents have previously been shown to have antiproliferative effects in tumor cells (Smith et al. 2002) but carry the risk for QT intervals and hence arrhythmias (Kiehn et al. 1999 ). Furthermore, it was recently shown that HERG K + channel blockage induced by doxazosin directly results in HEK cell apoptosis (Thomas et al. 2008) . It should be noted, however, that, while quinazoline α 1 -antagonists have been associated with apoptosis induction (Yang et al. 1997; Kyprianou et al. 1998; Chon et al. 1999; Anglin et al. 2002; Lin et al. 2007 ), they have not been implicated as having direct proarrhythmic potential (Thomas et al. 2004 ) possibly because clinically used doses of these drugs are insufficient to act on HERG channels to a relevant degree.
Apoptosis overinterpretation
Controversy and inconsistency has surrounded the apoptosis research as mediated by alpha blockers in target cells. Most would agree that the gold standard of apoptosis detection would be a detailed morphological analysis of each cell in a section by an expert microscopist. As this process would be user-dependent and not feasible for highthroughput quantitative assessment, other methods are commonly used. Much of the quinazoline α 1 -antagonist work, as stated above, has been driven by prostate histopathological studies in which the TUNEL technique has most frequently been the method of apoptotic index assessment. The technique, straightforward in its conception, involves labeling fragmented DNA in cells from histologic sections undergoing apoptosis by using TdT to transfer biotin UTP to the free 3′-OH broken end. The newly biotin-labeled sites are then visualized under fluorescence microscopy after reaction with fluoresceinconjugated avidin. Other commonly used methods of apoptosis detection include, but are not limited to, DNA fragmentation assay using gel electrophoresis (Gan et al. 2008) Proposed faults of the TUNEL technique attest that all nicks or breaks in DNA are labeled, whether resulting from apoptosis or other processes including active transcription, cell necrosis, or improper tissue preparation and handling (Gavrieli et al. 1992; Grasl-Kraupp et al. 1995; Yasuda et al. 1995; Kockx et al. 1998) . As a result, the TUNEL assay has proven to be adequately sensitive, but the possibility of false positives has left the specificity to be challenged. Subsequent study has found TUNEL assay specificity to exceed 87% (Kelly et al. 2003) and to also yield results strongly correlated with caspase-3 activation and caspase-cleaved CK18 prostate assays (Duan et al. 2003) . Thus, of current apoptosis assays, TUNEL is adequately apoptosis specific in prostate section analysis while producing results consistent with other common assays (Duan et al. 2003) .
Translational significance
Throughout the last decade, emerging knowledge has defined quinazoline α 1 -antagonists to have α 1 -independent, proapoptotic properties in multiple laboratory and clinical settings. In recent years, much progress has been made to better understand the clinical relevance of this information. Recent research regarding structural variants of the quinazoline α 1 -antagonists has yielded exciting anticancer pharmacologic potential. While the studies with known quinazolines have been important to establish this principle, doxazosin and related existing drugs are probably unsuitable for clinical apoptosis induction due to their α 1 -antagonist properties. However, they may be useful as starting points for the synthesis of more potent compounds. A recent pharmacologic exploitation of the doxazosin structure led to two structural variants of doxazosin that exhibit greater apoptosis-inducing action at lower concentrations (∼1-2 µM) than their parent compound (Shaw et al. 2004; Garrison and Kyprianou 2006) . Additional studies showed a lead doxazosin derivative to reduce endothelial cell viability, thus impeding tumor vascularity, in PC-3 and DU-145 prostate cancer xenografts (Garrison et al. 2007 ). Quinazoline α 1 -antagonists might be responsible for additional α 1 -independent growth-suppressing mechanisms including the activation of anoikis (loss of cellular adhesion to the extracellular matrix) via death receptor-signaling pathway and prevention of tumor cell invasion and migration Keledjian et al. 2005) . Further translational application of the antitumor potential of quinazoline α 1 -antagonists has shown the class to have synergistic effects with ionizing radiation in prostate cancer treatment (Cuellar et al. 2002) and to decrease the incidence of prostate cancer in patients previously treated with drugs from the class (Harris et al. 2007 ).
Tumor malignancy is dependent upon the continued ability to grow and spread to new tissues. These properties necessitate anoikis avoidance and continued angiogenesis. In turn, restoring or facilitating anoikis and inhibiting angiogenesis are two targets of anticancer therapy. Quinazoline-based drugs terazosin and doxazosin have been shown to facilitate anoikis in prostate cells by death receptormediated mechanisms involving death-inducing signaling complex formation/caspase-8 activation and inhibition of Akt survival signaling, consequential to the disruption of cell attachment to the extracellular matrix via targeting integrins (Shaw et al. 2004; Garrison and Kyprianou 2006; Garrison et al. 2007 ). These mechanisms are intimately connected with the ability of terazosin and doxazosin to induce TGF-β1-mediated apoptosis independent of α 1 -adrenoceptor action (Partin et al. 2003) . Terazosin and doxazosin have also been shown to α1-independently downregulate the vascular endothelial growth factor in prostate tissue, thus impairing angiogenesis in malignant prostate tumors .
In conclusion, quinazoline α 1 -antagonists are effective options in managing BPH as well as hypertension. Research has recently shown drugs in this class to have multiple α 1 -independent, anticancer properties. Future directions include continued detailed exploration of biochemical mechanisms responsible for the apoptotic effects exerted by the quinazolines and optimizing compounds that effectively demonstrate these effects in humans with limited side effects.
